PCV56 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION - ResearchGatedoi:10.1016/S1098-3015(10)73818-3Wolowacz...
This article provides an overview of the clinical profile of oral dabigatran etexilate (Pradaxa®, Pradax™) [hereafter referred to as dabigatran] when used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), followed by a review of cost-...
dabigatran etexilate oral 150 mg capsule dabigatran etexilate oral 150 mg capsule Copyright © 2010 First DataBank, Inc. Patient HandoutPatient Educationdabigatran etexilate oral DABIGATRAN - ORAL (DA-bi-GAT-ran) COMMON BRAND NAME(S): Pradaxa WARNING: Do not stop taking dabigatran unless...
The positive opinion from the CHMP for dabigatran etexilate represents another significant milestone in the history of stroke prevention in AF. When approved in the EU, dabigatran etexilate (150mg bid) will improve the lives of many patients by significantly reducing the risk of strokes compa...
Dabigatran Etexilate (PRADAXA) is a new oral anticoagulant increasingly used for a number of blood thrombosis conditions, prevention of strokes and systemic emboli among patients with atrial fibrillation. It provides safe and adequate anticoagulation for prevention and treatment of thrombus in several clin...
Bradley-Kennedy C, Wolowacz SE, Roskell NS, et al. Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery [abstract no. PP-WE-470]. J Thromb Haemost 2009; 7 Suppl. 2...
Background-The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and dabiga... AL Dans,SJ Connolly,L Wallentin,... - 《Circulation》 被引量: 499发表: 2013年 New oral anticoagulants in addition to single or dual...
Objectives To conduct a cost-utility evaluation of dabigatran etexilate compared with enoxaparin for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) and total hip replacement (THR) in Colombia. Methods An acute phase model, using decision analysis, and a long-term...
dabigatran 150mg (or age-adjusted, sequential dosing) was cost effective with regard to the incremental cost per QALY gained relative to adjusted-dose warfarin in the prevention of stroke and systemic embolism in AF patients, as the results were below generally accepted cost-effectiveness thresholds...
McKeage K. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Pharmacoeconomics 2012;30: 841-55.McKeage K (2012) Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke ...